| KLAC |
Report |
FQ4 Revenue |
BEAT |
pred ~$3.66B vs. cons $3.61B |
MEDIUM |
| KLAC |
Report |
FQ4 Non-GAAP EPS |
BEAT |
pred ~$10.05 vs. cons $9.87 |
MEDIUM |
| KLAC |
Report |
FQ4 Non-GAAP Gross Margin |
IN-LINE |
pred ~61.9% vs. cons 61.75% |
MEDIUM |
| KLAC |
Guide |
FQ1 FY2027 Revenue Guide |
BETTER |
guide ~$3.75B vs. cons $3.70B (Sept-quarter FY2027Q1) |
MEDIUM |
| KLAC |
Guide |
CY2026 WFE Market Outlook (>$140B) |
UNCHANGED |
guide ~$140B+ vs. cons $140B prior commentary (calendar 2026) |
MEDIUM |
| KLAC |
Guide |
Advanced Packaging Process Control Revenue 2026 |
BETTER |
guide ~$1.05B vs. cons/prior $1.0B (calendar 2026) |
LOW |
| KLAC |
Guide |
CY2026 Non-GAAP Gross Margin Target (~62%) |
UNCHANGED |
guide ~62% vs. cons 62% (calendar 2026, ±50bp, ~100bp DRAM headwind) |
MEDIUM |
| KLAC |
Return |
Day-1 residual (stock − beta × S&P 500) |
+4.5% |
— |
MEDIUM |
| KLAC |
Return |
5-day cumulative residual |
+2.0% (FADE) |
A likely beat-and-reiterate should spark an initial relief rally given the stock's ~33% drawdown from its June peak, but the out-period math (Sept-quarter guide implies deceleration from the seasonally strong sequential ramp, DRAM cost headwind persists, and China indigenous-toolmaker/CXMT competitive risk plus hyperscaler capex jitters remain unresolved) likely causes analysts to trim out-year estimates even after headline upside, fading much of the day-1 pop over the following week as the market re-litigates AI-capex durability across the semicap complex. |
MEDIUM |